Table 1

Patient characteristics and results of 99mTc-sestamibi imaging

Patient no.DiagnosisAge (yr)SexPrior chemotherapy with Pgp substratesa% change liver:heart 99mTc-sestamibib AUC0–3 hLung/chest wallcLivercLymph nodecBone/soft tissuec
No. of agentsNo. of doses
1Clear cell carcinoma58M00111INCdINCNV
2Clear cell carcinoma36M00130INCNVNV
3Clear cell carcinoma54M00114INCINCINC
4Clear cell carcinoma53M0075INCNVNV
5Clear cell carcinoma63M0059NVVINC
6Clear cell carcinoma44M00198NVNOT INC
7Papillary carcinoma63F00110NV
8Adrenal cancer43F330229NVNVNV
9Adrenal cancer69F324222INCNV
10Adrenal cancer32M332190INCINCNV
11Adrenal cancer31M348278INCNV
12Breast cancer80F211152NVNVNVINC
13Breast cancer55F22156NOT INCINCNOT INCINC
14Breast cancer55F32184NVNV
15Breast cancer57F35218NVNV
16Breast cancer52F16253NOT INC
17Ovarian carcinoma33F214167NVNVNVNV
18Ovarian carcinoma63F332174NV
19Ovarian carcinoma44F211−14NVNOT INCVNV
20Melanoma66F1348NV
21NSCLS49M29−3NOT INCNVNVNV
22Parotid gland carcinoma28F0067NOT INCNV
23Basal call carcinoma48M00111INC
24Cervical adenocarcinoma42F1295INCNV
25Ewing’s sarcoma35M260122NV
  • a Prior chemotherapy: each prior Pgp substrate administration was counted as a separate dose. Thus, for example, patient 8 was treated with 3 Pgp substrates on 10 successive cycles (3 × 10 = 30 doses); whereas patient 11 was treated with 3 Pgp substrates for a total of 16 cycles (3 × 16 = 48 doses).

  • b See “Patients and Methods” for calculation used to derive percentage change liver:heart 99mTc Sestamibi AUC0–3 h.

  • c Four columns on the right indicate sites of disease documented by exam or radiographic studies. Empty box = no metastatic disease at this site or organ.

  • d Results of 99mTc Sestamibi imaging are summarized as follows: INC, tumor mass visualized in baseline 99mTc-sestamibi image and tumor:heart AUC0–3 h increased after XR9576; NOT INC, tumor visualized in baseline 99mTc-sestamibi image but tumor:heart AUC0–3 h unchanged or decreased after XR9576; V, tumor visualized but not included in initial field of view, so change in AUC unknown; and NV, 99mTc-sestamibi imaging did not visualize tumor mass at baseline nor after XR9576 (in patients 7, 8, 14, 15, 17, 18, 20, and 25 tumors not visualized).